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Abstract
background: The effect of current therapies in improving the survival of lung cancer patients
remains far from satisfactory. It is consequently desirable to find more appropriate therapeutic
opportunities based on informed insights. A molecular pharmacological analysis was undertaken to
design an improved chemotherapeutic strategy for advanced lung cancer.
Methods:  We related the cytotoxic activity of each of commonly used anti-cancer agents
(docetaxel, paclitaxel, gemcitabine, vinorelbine, 5-FU, SN38, cisplatin (CDDP), and carboplatin
(CBDCA)) to corresponding expression pattern in each of the cell lines using a modified NCI
program.
Results: We performed gene expression analysis in lung cancer cell lines using cDNA filter and
high-density oligonucleotide arrays. We also examined the sensitivity of these cell lines to these
drugs via MTT assay. To obtain our reproducible gene-drug sensitivity correlation data, we
separately analyzed two sets of lung cancer cell lines, namely 10 and 19. In our gene-drug
correlation analyses, gemcitabine consistently belonged to an isolated cluster in a reproducible
fashion. On the other hand, docetaxel, paclitaxel, 5-FU, SN-38, CBDCA and CDDP were gathered
together into one large cluster.
Conclusion: These results suggest that chemotherapy regimens including gemcitabine should be
evaluated in second-line chemotherapy in cases where the first-line chemotherapy did not include
this drug. Gene expression-drug sensitivity correlations, as provided by the NCI program, may
yield improved therapeutic options for treatment of specific tumor types.
Published: 30 June 2006
BMC Cancer 2006, 6:174 doi:10.1186/1471-2407-6-174
Received: 20 November 2005
Accepted: 30 June 2006
This article is available from: http://www.biomedcentral.com/1471-2407/6/174
© 2006 Gemma et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2006, 6:174 http://www.biomedcentral.com/1471-2407/6/174
Page 2 of 7
(page number not for citation purposes)
Background
While various anti-cancer drugs have been developed,
many patients with solid tumors still exhibit poor progno-
sis. Accordingly, it is now important to determine the
appropriate use of such drugs clinically. With respect to
treatment of lung cancer, there are many anti-cancer
agents in use, such as cisplatin (CDDP), carboplatin
(CBDCA), docetaxel, paclitaxel, vinorelbine, gemicitab-
ine, 5-fluorouracil (5-FU), CPT-11, etc. A number of com-
bination therapy regimens employing platinum
compounds have proven to be effective[1] and are widely
applied to initial treatment for unresected non-small cell
lung cancer (NSCLC)[2]. In addition, docetaxel and
pemetrexed have been reported to be effective in the con-
text of second-line chemotherapy for NSCLC[3,4]. How-
ever, at present, the effect of these therapies on improving
patient survival remains far from satisfactory [1-3]. It is
consequently desirable to find more appropriate thera-
peutic opportunities based on informed insights. With the
recent near-completion of the human genome sequence,
genome-wide gene expression profiling through both
cDNA and oligonucleotide arrays has been greatly facili-
tated [5-7]. There are many reports associated with isola-
tion of molecules involved in drug sensitivity [8-10]. Of
particular relevance was the use of DNA array-based meth-
odology by the National Cancer Institute (NCI) to assess
the gene expression profiles of 60 human cancer cell lines
of diverse tissue origin (NCI60 set), with a view to deter-
mining associations with the extensive drug sensitivity
data accumulated on this cell line cohort so far[11]. The
NCI60 gene expression study was analogous in some
respects to assessment of clinical tumors for markers that
predict sensitivity to therapy. The essential aim of this
study was to utilize similar advanced gene expression pro-
filing technologies and drug sensitivity assays to aid in the
selection of appropriate drug combinations for the treat-
ment of lung cancer. We performed gene expression anal-
ysis in lung cancer cell lines using cDNA filter and high-
density oligonucleotide arrays. We also examined the sen-
sitivity of these cell lines to commonly used anti-cancer
agents (docetaxel, paclitaxel, gemcitabine, vinorelbine, 5-
FU, SN38, cisplatin (CDDP), and carboplatin (CBDCA))
via MTT assay. We related the cytotoxic activity of each of
these agents to the corresponding expression pattern in
each of the cell lines using a modified NCI program. To
obtain our reproducible gene-drug sensitivity correlation
data, we separately analyzed two sets of lung cancer cell
lines, namely 10 and 19.
Methods
Clustering on the basis of drug activity and gene expression 
patterns
Cell lines
We analyzed the expression profiles and sensitivity to
anti-cancer drugs of separate two sets of lung cancer cell
lines. The first set consisted of PC9, PC7, PC14, A549,
Lu65, LK2, H69, N231, Lu135, and SBC3 (Set 1). The sec-
ond consisted of RERF-LC-KJ, RERF-LC-MS, RERF-LC-AI,
PC1, PC3, PC6, PC10, Lu130, Lu139, Lu165, ABC-1, EBC-
1, LC2/ad, LC1/sq, LC-1F, SQ5, QG56, MS-1, and SBC5
(Set 2). The PC1, PC3, PC6, PC7, PC9, PC10, PC14, and
QG56 cell lines were obtained from IBL (Gumma, Japan).
The A549, NCI-H69, and NCI-N231 cell lines were
obtained from the American Type Culture Collection
(Rockville, MD)[12]. The Lu65 and Lu135 cell lines were
provided by Y. Shimosato and T. Terasaki (National Can-
cer Center Research Institute, Tokyo, Japan)[12]. The LK-
2 and SBC-3 cell lines were obtained from the Health Sci-
ence Research Resources Bank (Osaka, Japan). PC1, PC3,
PC6, PC10, Lu130, Lu139, and Lu165 cell lines were pro-
vided by S. Hirohashi (National Cancer Center Research
Institute, Tokyo, Japan). RERF-LC-KJ, LC2/ad, SQ5, LC1/
sq, LC-1F, RERF-LC-AI, and MS-1 cell lines were obtained
from the RIKEN Cell Bank (Ibaraki, Japan). RERF-LC-MS,
EBC-1, SBC5, and ABC-1 cell lines were purchased from
the Health Science Research Resources Bank (Osaka,
Japan). PC7, PC9, PC14, A549, Lu65, RERF-LC-KJ, RERF-
LC-MS, PC3, ABC-1, and LC2/ad are adenocarcinoma cell
lines. LK-2, RERF-LC-AI, PC1, PC10, EBC-1, LC1/sq, LC-
1F, SQ5, and QG56 are squamous cell cancer cell lines.
NCI-H69, NCI-N231, Lu135, SBC-3, PC6, Lu130, Lu139,
Lu165, MS-1, and SBC5 are small cell lung cancer cell
lines.
Assay for drug activity
Estimation of cytotoxicity in the above-mentioned cell
types was mediated by a rapid colorimetric assay for mito-
chondrial dehydrogenase activity, as previously
described[13]. Briefly, cells were seeded into 12-well
plates (Falcon, Lincoln Park, NJ). Following 24 hr expo-
sure to particular anti-cancer agents, the cells were washed
twice and incubated for a further 24 hr in drug-free
medium. Subsequently, the cells were incubated with 0.5
mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetra-
zolium bromide (MTT) for 4 hr. The blue formazan crys-
tals, formed by viable cells, were solubilized by the
addition of 10% n-dodecylsulfate sodium salt (SDS) in
0.01N HCl followed by overnight incubation. Samples
were then subjected to spectrophotometric analysis at 560
nm (Ultraspec 4050; LKB, Bromma, Sweden).
RNA isolation, cDNA array hybridization and analysis of 
hybridization signals
Total RNA was isolated from each cell line using standard
protocols described previously[14,15]. To avoid varia-
tions due to cell culture conditions, we cultured each
untreated cell line separately in 6 different flasks. mRNA
was then purified from total RNA by incubation with
oligo-dT-magnetic beads (Toyobo Co., Osaka, Japan)[16].
The ElectorGene Array System (GeneticLab. Co., Ltd. Sap-BMC Cancer 2006, 6:174 http://www.biomedcentral.com/1471-2407/6/174
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poro, Japan) was used for filter-based cDNA array analy-
sis, as previously reported[16]. Thirteen hundred species
of human DNA fragments are spotted in duplicate on a fil-
ter. The genes represented on this filter included cancer-
related and drug resistance-associated genes, as well as
housekeeping genes and non-mammalian genes as nega-
tive controls. To prepare the probes, reverse transcription
was performed using Reverse Transcriptase, ReverTraAce
(Toyobo Co., Osaka, Japan), together with a random 9
mer (Toyobo Co., Osaka, Japan) as the primer and 5 μg of
polyA RNA. The probes were labelled with biotin by
incorporation of biotin-16-deoxyuracil triphosphate
(dUTP) during the synthesis of cDNA. The filters were pre-
incubated in 20 ml of PerfectHyb (Toyobo Co., Osaka,
Japan) at 68°C for 30 min. The biotin-labeled probes
were denatured and added to the pre-hybridization solu-
tion. The filters were incubated overnight at 68°C in the
hybridization mixture. After washing, specific signals on
the filters were detected by the Imaging High – Chemi-
lumi – Detection kit (Toyobo Co., Osaka, Japan). CDP-
Star substrate (Tropix, Bedford, MA) was used as the
chemiluminescence substrate. A chemiluminescence
image of the filter was acquired by Fluor-S (Bio-Rad, Her-
cules, CA). The gene expression images were quantified by
measuring the intensity of the signals using Imagene (Bio-
Discovery, Los Angeles, CA). The signal intensity among
filters was analyzed by ElectorGene Finding System
(GeneticLab, Sapporo, Japan). The background threshold
was set at a level of 3-fold higher than the negative con-
trol. Signal intensities were normalized by comparison
with the average values of all probe. We also performed
high-density oligonucleotide array analysis using Affyme-
trix GeneChip technology (Affymetrix, Santa Clara, CA).
This oligonucleotide microarray contains 22,282 tran-
scripts (HG-U133A, Affymetrix, Santa Clara, CA). Total
RNA was used to synthesize double-strand cDNA with
ReverTraAce and a T7-(dT)24 primer (Metabion, Ger-
many). Then, biotinylated cRNA was synthesized from the
double-stranded cDNA using the RNA Transcript Labeling
kit (Enzo Life Sciences, Farmingdale, NY) and was puri-
fied and fragmented. The fragmented cRNA was hybrid-
ized to the oligonucleotide microarray, which was washed
and stained with streptavidine-phycoerythrin. Scanning
was performed with an Agilent Microarray Scanner (Agi-
lent Technologies, Palo Alto, CA). GeneChip analysis was
performed based on the Affymetrix GeneChip Mannual
(Affymetrix Inc., Santa Clara, CA) with Microarray Analy-
sis Suite (MAS) 5.0, Data Mining Tool (DMT) 2.0, and
Microarray Database software. The data we generated by
GeneChip was deposited in Gene Expression Omnibus
(GEO)(GEO accession: GSE4127)(17).
Data analysis
We performed data cleansing for filter arrays as follows.
Firstly, the gene expression matrix [T] was scaled by using
the average of all probe sets. Each of the filter arrays con-
tained three spots of negative control (pUC), so we fig-
ured out their average signal value M. We defined 3 M as
the threshold value, and transformed the numerical signal
values < 3 M to "Nan" (not a number). After omitting the
rows holding "Nan" more than one, we selected 600
genes for this analysis. Data analysis for the correlation
coefficients that related the drug activity patterns to the
expression patterns of the genes was principally per-
formed by a modified NCI program[11]. The symbol [A]
(GI50) refers to the drug activity matrix in which the rows
represent the anti-cancer drugs and the columns represent
the human lung cancer cell lines. The symbol [T] (gene
expression) refers to the gene expression matrix in which
the rows represent individual genes and the columns rep-
resent the cell lines. In order to analyze the relationship
between gene expression and drug activity, we generated
the gene-drug correlation matrix [AT] (correlation coeffi-
cient) in which the rows represent the genes and the col-
umns represent the drugs. Firstly, we subtracted its mean
value from the matrix [A] in the direction of row and col-
umns for a pre-treatment. Secondly, we normalized each
element in the matrix [A] by subtracting its row-wise
mean and dividing by its row-wise standard deviation;
normalized [T] was generated in a similar way. Finally, we
took the inner product of the matrix [A] and the transpose
of the matrix [T]. The resulting matrix [AT] implied the
Pearson correlation coefficients ( 1) that reflected the
relationship between drug activity and gene expression.
( 1) The Pearson correlation coefficient r is given by the
formula
Hierarchical clustering helps to comprehend a characteris-
tic of huge volumes of data. With cluster analysis, the ele-
ments are divided into groups that show similar patterns
by calculating the distances between their respective rows
and columns. The AT-clustered image map (CIM), indi-
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sion and drug sensitivity in the 10 human lung cancer cell
lines, was obtained by the linkage-average clustering
method, also known as UPGMA (un-weighted pair-group
method using arithmetic average). The statistical algo-
rithms and the graphical outputs described here were
implemented in MATLAB 6.5 Release 13 (the MathWorks,
Inc., US).
Results
Clustering on the basis of drug activity and gene expression 
patterns
We used filter-based DNA arrays, representing 1,302 can-
cer-related and drug resistance-associated genes, and
Affymetrix GeneChip technology to perform gene expres-
sion profile analysis of 10 human cancer cell lines. To
avoid the influence of cell culture conditions, we sepa-
rately cultured each cell line in 6 bottles[16]. The controls
including GAPDH, β-actin genes, were located in dupli-
cate at the outer line in the opposite angle. A standard
curve was obtained by the calculation of serial diluted
spots of GAPDH. The expression level of each gene was
calculated by comparison with the internal standard.
Drug sensitivity tests, namely by MTT analysis, were per-
formed on the 10 lung cancer cell lines. Eight anti-cancer
drugs currently used for lung cancer chemotherapy;
docetaxel, paclitaxel, gemcitabine, vinorelbine, 5-FU,
SN38, CDDP, and CBDCA, were selected for our analyses.
Table 1 shows the growth inhibitory activities (GI50) lev-
els of these anti-cancer agents against the lung cancer cell
lines. We then analyzed the gene expression profiling data
in relation to the activity profiles of the 8 drugs examined.
The drugs were clustered on the basis of Pearson correla-
tion coefficients that related their activity patterns across
the 10 cell lines to the expression pattern of the genes in
the cell lines[11]. The AT-matrix clustered image map
(CIM) summarized the relationship between drug sensi-
tivity and gene expression, as it allows the visualization of
patterns of similarity in large sets of high-dimensional
data (Fig. 1B)[16]. In this analysis, gemcitabine were
located in separate clusters (Fig. 1A). We performed an
analogous gene expression profiling screen using Affyme-
trix GeneChip arrays, receiving the same results with
respect to drug clusters (Fig. 1B). The results of the analy-
sis of NSCLC cell lines was similar to that seen with all
lung cancer cell lines (Figure 2A,B). However, it is some-
times difficult to consistently reproduce data of the gene-
drug sensitivity correlation using cDNA array technique
and clinical response data. To obtain reproducible data,
we separately performed Affymetrix GeneChip array-
based gene expression profile analyses and sensitivity tests
on another set of 19 human lung cancer cell lines and
examined the sensitivity of these separate sets to 8 com-
monly used anti-cancer agents. Table 2 shows the GI50
levels of these anti-cancer agents against the lung cancer
cell lines (Set 2) [see Additional file 1]. The drugs were
clustered using Set 2, 19 cell lines (Set 2)[11]. In this anal-
ysis, gemcitabine was again located in separate clusters
(Fig. 3A). The results of the analysis of NSCLC cell lines of
Set 2 was also similar (Fig. 3B). Several genes, were com-
monly listed that differentiated gemcitabine from the oth-
Clustered image map (CIM) relating drug activity to gene  expression in lung cancer cell lines – Experiment 1 Figure 1
Clustered image map (CIM) relating drug activity to gene 
expression in lung cancer cell lines – Experiment 1. (A) using 
filter array, (B) using GeneChip. The cluster trees of drugs (y 
axis) and gene expression (x axis) were shown in the CIM. 
Each block of colors represents correlations between clus-
ters of genes and drugs; red (high positive correlation) and 
blue (negative correlation). In this analysis, gemcitabine 
belonged to an isolated cluster (Fig. 1A,B). GEM; gemcitab-


















Table 1: Growth inhibitory activities (GI50)(μg/ml) of various anti-cancer agents against 10 human lung cancer cell lines – Set 1
Drug
PC7 PC9 PC14 A549 Lu65 LK-2 H69 N231 Lu135 SBC-3
CDDP 4.55 3.53 2.86 5.46 3.39 4.72 1.64 1.25 0.22 4.84
SN38 5.05 3.45 3.79 6.80 0.48 4.25 0.77 0.66 0.05 0.07
VIN 2.64 1.43 >10 >10 0.06 0.02 0.02 0.01 0.02 0.51
DOC 2.46 21.34 20.38 21.31 3.61 26.31 4.72 6.04 0.53 >50
GEM <0.05 14.28 >500 >500 79.53 54.61 3.73 3.88 <0.05 <0.05
5FU 2.76 5.84 >10 >10 8.76 >10 >10 >10 5.68 0.51
CBDCA 95 70 >100 46.3 71 0.225 7.54 45 61 3.5
PAC 6.7 39 34 51 34 20 <0.001 7 5.5 0.5BMC Cancer 2006, 6:174 http://www.biomedcentral.com/1471-2407/6/174
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ers in Sets 1 and 2. These were a LEMT1 domain
containing gene (Accession No. NM_015416), a dehydro-
genase gene (Accession No. AL050217), and a gene of
homo sapiens hypothetical protein (Accession No.
NM_016402). A LEMT1 domain containing gene was
reported to contribute to neoplastic cellular transforma-
tion[18]. A dehydrogenase gene constitutes a large protein
family of NAD(P)(H)-dependent oxidoreductase[19]. A
gene of homo sapiens hypothetical protein is similar to a
heat shock 70kDa protein 8 isoform[20]. Presently, their
functions involved in drug sensitivity remains unclear.
Discussion
Here, we used a DNA array-based gene expression profil-
ing approach, together with assessment of the cytotoxic
activity of several widely applied anti-cancer agents, in
two collections of human lung cancer cell lines. In partic-
ular, we related gene expression and drug sensitivity pat-
terns in these cell lines. According to our separate two
combined cytotoxicity and transcriptomic analyses, gem-
citabine belonged to an isolated cluster. These results
would suggest that combination chemotherapy regimens
including gemcitabine could be a candidate for initial
treatment, because combinations of drugs belonging to
different clusters could expand the spectrum of the chem-
otherapy. Gemcitabine was deemed from our studies to
be a good candidate for the treatment of recurrent or
refractory NSCLC. Recently, an in silico search was per-
formed to identify genes whose expression was positively
or negatively correlated with sensitivity to four platinum
compounds (CDDP, CBDCA, oxaliplatin and tetraplatin);
the publicly available databases of the National Cancer
Institute (NCI)(21) were used for this purpose[22].
CDDP, CBDCA, oxaliplatin and tetraplatin are platinum-
based compounds that are classically thought to have a
similar spectrum of activities, allowing for one agent to be
substituted for the other[23]. Important similarities were
noticed between CDDP and CBDCA on one hand, and
tetraplatin and oxaliplatin on the other hand[22]. The
gene-drug correlations using NCI program in these study
may be a valuable tool for the identification of determi-
nants of anticancer drug activity in tumors and for the
design of cancer chemotherapy.
Vekris et al. described several limitations to the type of
study that they have developed. 1. The evaluation of gene
expression was performed on a subset of 1416 genes and
molecular markers. 2. The level of expression of the 1416
molecular markers was determined with a technique that
was still under development and not fully validated. 3.
The criterion for drug cytotoxicity that has been retained
by the NCI is the 50% growth inhibitory concentration
(GI50) rather than the overall number of cells killed.
There were several differences between the study of Vekris
et al. and ours, most notably with respect to the cell lines
analyzed in each case. Our study focused on lung cancer
cell lines, whereas Vekris et al. utilized available informa-
tion on the NCI60 set, a wide range of cancer cell
lines[22]. The evaluation of gene expression by Vekris et
al. was performed on a subset of 1,416 genes, which rep-
resents a relatively small fraction of the total transcrip-
tome. We analyzed gene expression using two different
Clustered image map (CIM) relating drug activity to gene  expression in lung cancer cell lines using GeneChip – Experi- ment 2 Figure 3
Clustered image map (CIM) relating drug activity to gene 
expression in lung cancer cell lines using GeneChip – Experi-
ment 2. (A) all lung cancer cell lines, (B) NSCLC. The cluster 
trees of drugs (y axis) and gene expression (x axis) were 
shown in the CIM. Each block of colors represents correla-
tions between clusters of genes and drugs; red (high positive 
correlation) and blue (negative correlation). In this analysis, 
gemcitabine belonged to an isolated cluster (Fig. 3A,B). GEM; 
gemcitabine, PAC; paclitaxel, DOC; docetaxel, VIN; vinorel-
bine

















Clustered image map (CIM) relating drug activity to gene  expression in NSCLC cell lines – Experiment 1 Figure 2
Clustered image map (CIM) relating drug activity to gene 
expression in NSCLC cell lines – Experiment 1. (A) using fil-
ter array, (B) using GeneChip. The cluster trees of drugs (y 
axis) and gene expression (x axis) were shown in the CIM. 
Each block of colors represents correlations between clus-
ters of genes and drugs; red (high positive correlation) and 
blue (negative correlation). In this gemcitabine belonged to 
an isolated cluster (Fig. 2A,B). GEM; gemcitabine, PAC; pacli-
taxel, DOC; docetaxel, VIN; vinorelbine
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DNA array formats, namely spotted filter (data not
shown) and genome-wide GeneGhip arrays, with similar
results being obtained. In addition, we separately ana-
lyzed two sets of lung cancer cell lines, 10 and 19 lines to
obtain our reproducible gene-drug sensitivity correlation
data.
Using cDNA array technique and clinical response data, it
is sometimes difficult to consistently reproduce gene-drug
sensitivity correlation data. These data were often influ-
enced by sampling methods, sample preservation status,
tumor size, tumor environment status including tumor
vessels and inflammation, etc. In the study of Vekris et al.
and ours, these influences were small because cancer cell
lines were used. However, cell lines differ from tumor cells
and should therefore be considered as surrogates that may
contain information on the molecular cell biology and
molecular pharmacology of cancer.
In the treatment of lung cancer, a number of combination
therapy regimens employing platinum compounds have
proven to be effective[1] and are widely applied as first-
line treatment for unresected NSCLC; for example, CDDP
+ docetaxel, CBDCA + paclitaxel, CDDP + gemcitabine,
CDDP + CPT-11, CDDP + paclitaxel, CDDP + vinorelbine,
etc[2]. In addition, docetaxel and pemetrexed have been
reported to be effective in the context of second-line
chemotherapy for NSCLC[3,4]. However, how were the
anti-cancer agents in these reports selected? It is conse-
quently desirable to find more appropriate therapeutic
opportunities based on informed insights.
Conclusion
The results of our molecular pharmacological analysis
suggest that chemotherapy regimens including gemcitab-
ine should be evaluated in second-line chemotherapy if
the initial chemotherapy does not include this drugs. A
total design approach to cancer chemotherapy through
the gene-drug correlations using NCI program may yield
improved therapeutic options.
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